Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series

Amir Iravani, Catherine Mitchell, Tim Akhurst, Shahneen Sandhu, Michael S. Hofman, Rodney J. Hicks

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

• Molecular imaging targeting the prostate-specific membrane antigen, somatostatin receptor subtype 2, and glycolytic pathway may further enhance our understanding of the heterogeneity of the neuroendocrine differentiation of prostate cancer in a non-invasive manner and on a whole-body scale. • Molecular imaging heterogeneity of the neuroendocrine differentiation of prostate cancer may have important implications on the selection of patients for radionuclide therapy. • Coexisting neuroendocrine differentiation of prostate cancer and adenocarcinoma of the prostate within one biopsy sample or across a patient further supports the use of molecular imaging to verify the biologic target expression on a whole-body scale.

Original languageEnglish
Pages (from-to)e200-e205
JournalClinical Genitourinary Cancer
Volume19
Issue number4
DOIs
StatePublished - Aug 2021

Keywords

  • Fluorodeoxyglucose
  • Neuroedocrine differentiation of prostate cancer
  • Prostate-specific membrane antigen
  • Radionuclide therapy
  • Somatostatin receptor

Fingerprint

Dive into the research topics of 'Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series'. Together they form a unique fingerprint.

Cite this